Clinical Trial Update: An Efficacy and Safety Study of Intravenous Anifrolumab to Treat Systemic Lupus Erythematosus in Pediatric Participants [Phase 3]

View source ↗

Summary

Phase 3 pediatric trial evaluating intravenous anifrolumab for systemic lupus erythematosus is currently recruiting.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Systemic Lupus Erythematosus

Drugs mentioned

• Anifrolumab (anifrolumab)

Snippet

Sponsor: AstraZeneca | Conditions: Systemic Lupus Erythematosus | Phase 3 | Status: RECRUITING